Sign in Subscribe
COVID-19

SARS-CoV-2 Vaccines Show Promising Efficacy in Mitigating COVID-19 Pandemic

Strategic Insights

— 1 min read

Researchers from the University of Texas MD Anderson Cancer Center have made significant findings in the development of SARS-CoV-2 vaccines. According to a study published in JCI Insight, the high-degree efficacy of SARS-CoV-2 vaccines in clinical trials indicates that vaccination invariably induces an adaptive immune response. However, the emergence of breakthrough infections in vaccinated individuals suggests that the breadth and magnitude of vaccine-induced adaptive immune response may vary.

Key Takeaways:

  • SARS-CoV-2 vaccines have shown high-degree efficacy in clinical trials, inducing an adaptive immune response in vaccinated individuals.
  • The emergence of breakthrough infections in vaccinated individuals indicates that the breadth and magnitude of vaccine-induced adaptive immune response may vary.
  • Researchers identified two distinct response groups: individuals with high abundance versus low abundance of SARS-CoV-2-specific T cells.
  • The fractions of TNF-alpha- and IL-2-producing SARS-CoV-2 T cells were the main determinants distinguishing high versus low responders.
  • The majority of vaccine-induced SARS-CoV-2 T cells were reactive against non-mutated regions of mutant S-protein, suggesting that vaccine-induced SARS-CoV-2 T cells could provide continued protection against emerging variants of concern.
  • The study investigated differentiation states and cytokine profiles to identify immune features associated with superior recall function and longevity.
  • Researchers found that SARS-CoV-2-specific CD4(+) T cells were polyfunctional and produced high levels of IL-2, which could be associated with superior longevity.

Statistics:

  • 21 vaccinated individuals were assessed in the study.
  • The study found that SARS-CoV-2-specific T cells were invariably detected in all individuals.
  • The majority of vaccine-induced SARS-CoV-2 T cells (73%) were reactive against non-mutated regions of mutant S-protein.
  • The study found that the fractions of TNF-alpha- and IL-2-producing SARS-CoV-2 T cells were the main determinants distinguishing high versus low responders.

Sources:

  • In-depth Analysis of Sars-cov-2-specific T Cells Reveals Diverse Differentiation Hierarchies In Vaccinated Individuals. JCI Insight, 2022;7(7).
  • NewsRx. Researchers from University of Texas MD Anderson Cancer Center Describe Findings in COVID-19 (In-depth Analysis of Sars-cov-2-specific T Cells Reveals Diverse Differentiation Hierarchies In Vaccinated Individuals). Vaccine Weekly. May 25, 2022; p 674.

Read more